Arcadia Biosciences (RKDA) Gains from Investment Securities (2016 - 2025)
Arcadia Biosciences' Gains from Investment Securities history spans 12 years, with the latest figure at -$2.0 million for Q4 2025.
- For Q4 2025, Gains from Investment Securities fell 2425.58% year-over-year to -$2.0 million; the TTM value through Dec 2025 reached -$1.8 million, down 1257.86%, while the annual FY2025 figure was $179963.0, 13.9% up from the prior year.
- Gains from Investment Securities reached -$2.0 million in Q4 2025 per RKDA's latest filing, down from $25000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $2.3 million in Q2 2022 to a low of -$2.0 million in Q4 2025.
- Average Gains from Investment Securities over 5 years is $80467.5, with a median of $26021.0 recorded in 2023.
- Peak YoY movement for Gains from Investment Securities: soared 761.54% in 2024, then tumbled 2425.58% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at -$369000.0 in 2021, then soared by 172.18% to $266347.0 in 2022, then plummeted by 104.88% to -$13000.0 in 2023, then skyrocketed by 761.54% to $86000.0 in 2024, then crashed by 2425.58% to -$2.0 million in 2025.
- Per Business Quant, the three most recent readings for RKDA's Gains from Investment Securities are -$2.0 million (Q4 2025), $25000.0 (Q3 2025), and $25000.0 (Q2 2025).